Ocean Biomedical, Inc. (OCEA)
OTCMKTS
· Delayed Price · Currency is USD
0.0101
-0.0004 (-3.81%)
May 13, 2025, 3:58 PM EDT
Ocean Biomedical Employees
Ocean Biomedical had 7 employees as of December 31, 2024. The number of employees decreased by 2 or -22.22% compared to the previous year.
Employees
7
Change
-2
Growth
-22.22%
Revenue / Employee
n/a
Profits / Employee
-$1,354,286
Market Cap
1.68M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7 | -2 | -22.22% |
| Dec 31, 2021 | 9 | 1 | 12.50% |
| Dec 31, 2020 | 8 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Endo Inc. | 3,116 |
| Tian'an Technology Group | 8 |
| CytoDyn | 9 |
| Glass House Brands | 374 |
| Elite Pharmaceuticals | 64 |
| Northwest Biotherapeutics | 25 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
Ocean Biomedical News
- 3 months ago - Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development - GlobeNewsWire
- 3 months ago - Ocean Biomedical Advances Malaria Vaccine Research with New NIH Funding and Expedited Development Pathway - GlobeNewsWire
- 6 months ago - Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q - GlobeNewsWire
- 7 months ago - Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter - GlobeNewsWire
- 7 months ago - Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors. - GlobeNewsWire
- 8 months ago - Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses - GlobeNewsWire
- 9 months ago - Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company's Malaria Treatment and Prevention Platforms - GlobeNewsWire
- 1 year ago - Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024 - GlobeNewsWire